Goldman Sachs analysts removed Amgen (AMGN) from the firm’s US Conviction List as part of its monthly update.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen price target lowered to $330 from $360 at RBC Capital
- Dow Jones Slips as Amgen and Intel Drag It Down
- Viking’s VK2735 outpacing Amgen’s MariTide, says H.C. Wainwright
- Amgen (NASDAQ:AMGN) Sinks despite Positive MariTide Trial Data
- Weight loss drugmakers in spotlight as White House proposes coverage
